AVX-701
/ Duke University Health System, AlphaVax
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
August 09, 2016
Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer
(clinicaltrials.gov)
- P1; N=12; Recruiting; Sponsor: Duke University; Trial primary completion date: Jun 2016 ➔ Jun 2017
Trial primary completion date • Biosimilar • Colorectal Cancer • Gastrointestinal Cancer • Oncology
July 18, 2019
Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer
(clinicaltrials.gov)
- P1; N=12; Completed; Sponsor: Duke University; Active, not recruiting ➔ Completed
Clinical • Trial completion
January 16, 2019
Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer
(clinicaltrials.gov)
- P1; N=12; Active, not recruiting; Sponsor: Duke University; Trial completion date: Nov 2018 ➔ Jun 2019
Clinical • Trial completion date
1 to 3
Of
3
Go to page
1